Claims

1. A combination, comprising:

as a first active ingredient, 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a pharmaceutically acceptable salt thereof, and

as a second active ingredient, pyronaridine or a pharmaceutically acceptable salt thereof.

2. The combination according to claim 1, which further comprises:

as a third active ingredient, artemisinin or a derivative or pharmaceutically acceptable salt thereof.

3. The combination according to claim 2, wherein the artemisinin derivative is selected from the group consisting of dihydroartemisin, artemether, and artesunate.

4. The combination according to claim 3, wherein the third active ingredient is artesunate or a pharmaceutically acceptable salt thereof.

5. The combination according to claim 4, wherein the pharmaceutically acceptable salt of artesunate is salt selected from the group consisting of sodium salts and potassium salts.

6. The combination according to claim 2, wherein the combination comprises:

6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide,

pyronaridine tetraphosphate, and

sodium artesunate.

7. The combination according to claim 1, wherein the first active ingredient and the second active ingredient are administered simultaneously or sequentially.

8. A pharmaceutical composition, comprising:

as active ingredients,

therapeutically active doses of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a pharmaceutically acceptable salt thereof, and

pyronaridine or a pharmaceutically acceptable salt thereof, and

at least one pharmaceutically acceptable excipient,

for the treatment and/or prevention of malaria.

9. The pharmaceutical composition according to claim 8, comprising:

as a further active ingredient, a therapeutically active dose of artemisinin or a derivative or pharmaceutically acceptable salt thereof.

10. A kit for the treatment of malaria, comprising:

firstly 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a pharmaceutically active salt thereof, and

secondly pyronaridine or a pharmaceutically active salt thereof.

11. The kit according to claim 10, which further comprises:

artemisinin or a derivative or pharmaceutically acceptable salt thereof.

12. Use of a therapeutically active amount of a combination of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a pharmaceutically acceptable salt thereof, and

pyronaridine or a pharmaceutically acceptable salt thereof, including mixtures thereof in all ratios, in the manufacture of a medicament for the treatment and/or prevention of malaria in a patient in need thereof, wherein said medicament is to be administered to such patent.

13. The use according to claim 12, wherein the combination further comprises artemisinin or a derivative or pharmaceutically acceptable salt thereof.